ACE2 and injury: It was recently demonstrated that recombinant ACE2 is effective for treating SARS-CoV-2 RBD protein-aggravated LPS-induced acute lung injury in a mouse experimental model and that the protection occurs by acting on the ACE2-AngII-AT1R-NOX1/2 axis that is otherwise overactivated by the SARS-CoV-2 infection (Zhang et al., 2022).